In vascular injury models, BPC-157 promotes healing of blood vessel damage and prevents pathological thrombus formation while supporting physiological hemostasis
(USP) If the product is being promoted primarily through a med-spa, influencer, or affiliate funnel rather than a real prescribing relationship, caution should also increase
Moreover, the small number of trials and the potential presence of confounding factors further complicate the interpretation of these results
A recent 2022 Phase 2 randomized, double-blind, placebo-controlled trial funded by the NIH evaluated the effects of D-Ribose and Ubiquinol in patients with heart failure with preserved ejection fraction (HFpEF)
This was just confirmed by my colleague, Keith Humphreys, at Stanford
Notably, linagliptins ability to block this interaction in an in vitro system lacking GLP-1 suggests an M6P-mediated approach independent of GLP-1 (unpublished data)